Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial

Delafloxacin is a novel fluoroquinolone with activity against Gram-positive, Gram-negative, and atypical pathogens, including fluoroquinolone-nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA). The microbiological results of a phase 3 clinical trial in adults with community-acquired p...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Antimicrob Agents Chemother
Hlavní autoři: McCurdy, Sandra, Keedy, Kara, Lawrence, Laura, Nenninger, Ashley, Sheets, Amanda, Quintas, Megan, Cammarata, Sue
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2020
Témata:
Clinical Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7038307/
https://ncbi.nlm.nih.gov/pubmed/31844013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01949-19
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky